AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30143383 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic prostatectomy (RALP)
Number of subjects: 2638
Study 30143383 — intervention group
Group type: COMPARATOR
Intervention: Radical retropubic prostatectomy (RRP)
Number of subjects: 2638
Study 28885034 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FRD)
Number of subjects: 38
Study 28885034 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FRD) with miniscrew anchorage
Number of subjects: 38
Study 28885034 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study 25790670 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC) - 3 pills each time, 3 times a day for 3 months
Number of subjects: 120
Study 25790670 — intervention group
Group type: COMPARATOR
Intervention: SASP (sulfasalazine) - 4 tablets each time, twice a day for 3 months
Number of subjects: 120
Study 25790670 — intervention group
Group type: EXPERIMENTAL
Intervention: XFC
Number of subjects: 120
Study 23327229 — intervention group
Group type: COMPARATOR
Intervention: Adper Single Bond Plus
Number of subjects: 156
Study 23327229 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Scotchbond SE
Number of subjects: 156
Study 23327229 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Easy Bond
Number of subjects: 156
Study 21612139 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg of Ringer's lactate (RL)
Number of subjects: 90
Study 21612139 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL/kg of Ringer's lactate (RL)
Number of subjects: 90
Study 21612139 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL/kg of Ringer's lactate (RL)
Number of subjects: 90
Study 19422345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir (for 21 days) followed by once daily valganciclovir until day 49
Number of subjects: 321
Study 19422345 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir (twice daily for 21 days)
Number of subjects: 321
Study 19422345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (valganciclovir and ganciclovir)
Number of subjects: 321
Study 16949694 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (CFRT) with 64 Gy
Number of subjects: 51
Study 16949694 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (CFRT) with 74 Gy
Number of subjects: 51
Study 16949694 — intervention group
Group type: EXPERIMENTAL
Intervention: D90 > or = 50 Gy to the penile bulb
Number of subjects: 51
Study 16949694 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of dose to the penile bulb and crura
Number of subjects: 51
Study 15719855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (10 mg)
Number of subjects: 40
Study 15719855 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (10 mg)
Number of subjects: 40
Study 15719855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 11564483 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa 100 mg
Number of subjects: 53
Study 11564483 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study 9643623 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 180 mg and trandolapril 0.5 mg
Number of subjects: 456
Study 9643623 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 180 mg and trandolapril 1.0 mg
Number of subjects: 456
Study 9643623 — intervention group
Group type: COMPARATOR
Intervention: Verapamil SR (120, 180 mg) and trandolapril (0.5, 1.0, 2.0 mg)
Number of subjects: 456
Study 7941937 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 40
Study 7941937 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 40
Study 3062528 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% levobunolol before unilateral Nd:YAG laser posterior capsulotomy
Number of subjects: 83
Study 3062528 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% levobunolol after unilateral ECCE
Number of subjects: 83
Study 31319747 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 28
Study 31319747 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine without a vasoconstrictor
Number of subjects: 28
Study 31319747 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lidocaine with and without epinephrine
Number of subjects: 28
Study 27642762 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 202
Study 27642762 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time intervention
Number of subjects: 202
Study 26053604 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic foam 1 (n = 53)
Number of subjects: 105
Study 26053604 — intervention group
Group type: COMPARATOR
Intervention: Viscoelastic foam 2 (n = 52)
Number of subjects: 105
Study 23769023 — intervention group
Group type: EXPERIMENTAL
Intervention: HMP through hepatic artery (HA) alone
Number of subjects: 16
Study 23769023 — intervention group
Group type: EXPERIMENTAL
Intervention: HMP through HA and portal vein (PV)
Number of subjects: 16
Study 23769023 — intervention group
Group type: EXPERIMENTAL
Intervention: HMP through PV alone
Number of subjects: 16
Study 23769023 — intervention group
Group type: COMPARATOR
Intervention: ≥8 hours cold storage (CS)
Number of subjects: 16
Study 21577010 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg opipramol
Number of subjects: 72
Study 21577010 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg opipramol
Number of subjects: 72
Study 21577010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19736554 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIPOI‐1 (basic information on overweight and health, screening for overweight)
Number of subjects: 79
Study 19736554 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIPOI‐2 (education on nutrition, physical activity, and sedentary behaviors)
Number of subjects: 79
Study 19736554 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention kindergartens)
Number of subjects: 79
Study 16490494 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-piece acrylic IOL
Number of subjects: 105
Study 16490494 — intervention group
Group type: COMPARATOR
Intervention: Three-piece silicone IOL
Number of subjects: 105
Study 16490494 — intervention group
Group type: COMPARATOR
Intervention: One-piece acrylic IOL
Number of subjects: 105
Study 15799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Shelhigh prosthesis
Number of subjects: 327
Study 15799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-valve replacement (both Shelhigh)
Number of subjects: 327
Study 15799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Shelhigh prosthesis with concomitant mitral valve reconstruction
Number of subjects: 327
Study 15799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Homografts
Number of subjects: 327
Study 15799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve reconstruction
Number of subjects: 327
Study 15799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement due to severe damage
Number of subjects: 327
Study 15799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Other types of surgery
Number of subjects: 327
Study 15799913 — intervention group
Group type: COMPARATOR
Intervention: Homografts vs Shelhigh stentless prosthesis
Number of subjects: 327
Study 15799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 327
Study 15799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for mortality
Number of subjects: 327
Study 11273498 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) therapy, 5 million units (MU) subcutaneously thrice a week for 12 weeks
Number of subjects: 54
Study 11273498 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (Control)
Number of subjects: 54
Study 9109139 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin once daily (qd)
Number of subjects: 158
Study 9109139 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin twice daily (bid)
Number of subjects: 158
Study 9109139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 9109139 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (qd or bid)
Number of subjects: 158
Study 9109139 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (qd) vs. Amoxicillin (bid)
Number of subjects: 158
Study 9109139 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (qd or bid) vs. Placebo
Number of subjects: 158
Study 1394811 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Adriamycin (ADM) + 200 mg cytosine arabinoside (CA) in 30 ml physiological saline (group A)
Number of subjects: 314
Study 1394811 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg peplomycin (PEP) + 200 mg CA in 30 ml physiological saline (group B)
Number of subjects: 314
Study 1394811 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg neocarzinostatin (NCS) + 200 mg CA in 30 ml physiological saline (group C)
Number of subjects: 314
Study 1394811 — intervention group
Group type: COMPARATOR
Intervention: Control group (group D)
Number of subjects: 314
Study 1394811 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 300 mg/day UFT (group E)
Number of subjects: 314
Study 1394811 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 200 mg 5‐fluorouracil (5‐FU)/day (group F)
Number of subjects: 314
Study 1394811 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 30 mg ubenimex/day (group G)
Number of subjects: 314
Study 1394811 — intervention group
Group type: COMPARATOR
Intervention: No oral drug (group H)
Number of subjects: 314
Study 3840612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromopride (20 mg) administered via i.v. injection half an hour before chemotherapy and at 3 1/2 and 7 1/2 hours following chemotherapy.
Number of subjects: 35
Study 3840612 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered via i.v. injection half an hour before chemotherapy and at 3 1/2 and 7 1/2 hours following chemotherapy.
Number of subjects: 35
Study 3840612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromopride (20 mg)
Number of subjects: 35
Study 3840612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 29283904 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐spectrum colonoscopy with the Fuse system (330 degrees)
Number of subjects: 249
Study 29283904 — intervention group
Group type: COMPARATOR
Intervention: Standard forward‐viewing colonoscopy (170 degrees)
Number of subjects: 249
Study 30095608 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 26
Study 30095608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 26
Study 25256380 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training (BF)
Number of subjects: 12
Study 25256380 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 12
Study 24011750 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (video and written information)
Number of subjects: 132
Study 24011750 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 132
Study 22368996 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology treatment for a period of 6 months
Number of subjects: 100
Study 22368996 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 19373423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole
Number of subjects: 821
Study 19373423 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo, H2 receptor antagonist, or somatostatin)
Number of subjects: 821
Study 17499091 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etching adhesives (G-Bond, iBond, Clearfil S(3))
Number of subjects: 24
Study 17499091 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etching adhesives (Clearfil SE, Optibond Solo Plus Self-Etch)
Number of subjects: 24
Study 17499091 — intervention group
Group type: COMPARATOR
Intervention: Total-etch adhesive (Prime & Bond NT)
Number of subjects: 24
Study 15848824 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based community simulation
Number of subjects: 14
Study 15848824 — intervention group
Group type: COMPARATOR
Intervention: traditional assignment
Number of subjects: 14
Study 11590678 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-radiation therapy ((188)Re-MAG(3))
Number of subjects: 50
Study 11590678 — intervention group
Group type: COMPARATOR
Intervention: Control (rotational atherectomy and balloon angioplasty)
Number of subjects: 50
Study 9833601 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (500 or 750 mg daily for 12 weeks)
Number of subjects: 18
Study 9833601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 weeks)
Number of subjects: 18
Study 9695160 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human growth hormone over eight weeks
Number of subjects: 10
Study 9695160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1677821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.10 mg/kg)
Number of subjects: 48
Study 1677821 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.09 mg/kg)
Number of subjects: 48
Study 6307135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g twice daily
Number of subjects: 100
Study 6307135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once daily
Number of subjects: 100
Study 6307135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone therapy continued after discharge
Number of subjects: 100
Study 6307135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone therapy
Number of subjects: 100
Study 30622317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 38
Study 30622317 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg
Number of subjects: 38
Study 30128705 — intervention group
Group type: EXPERIMENTAL
Intervention: Talcom 75 mg od + aspirin 100 mg od
Number of subjects: 248
Study 30128705 — intervention group
Group type: COMPARATOR
Intervention: Plavix 75 mg od + aspirin 100 mg od
Number of subjects: 248
Study 30128705 — intervention group
Group type: EXPERIMENTAL
Intervention: Talcom
Number of subjects: 248
Study 30128705 — intervention group
Group type: COMPARATOR
Intervention: Plavix
Number of subjects: 248
Study 27423688 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis reported in RCTs
Number of subjects: 437
Study 27423688 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate methods for subgroup analysis
Number of subjects: 437
Study 27423688 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis reporting by year
Number of subjects: 437
Study 27423688 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of appropriate methods over time
Number of subjects: 437
Study 27423688 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of reporting subgroup analysis
Number of subjects: 437
Study 27423688 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of appropriate methods in industry-funded trials
Number of subjects: 437
Study 27423688 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination of subgroup effects using multivariable risk index
Number of subjects: 437
Study 24476457 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual admission
Number of subjects: 50
Study 24476457 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital admission
Number of subjects: 50
Study 22763336 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with ACS
Number of subjects: 1947
Study 21108204 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (bolus 1 mg/kg, followed by increments containing 20% of the initial dose)
Number of subjects: 100
Study 21108204 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (bolus 0.15 mg/kg, followed by increments containing 20% of the initial dose) and 1 mg/kg of fentanyl i.v. (single dose)
Number of subjects: 100
Study 18751504 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of terbinafine (250 mg)
Number of subjects: 19
Study 18751504 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of terbinafine (250 mg)
Number of subjects: 19
Study 15998354 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH(1-24) 1.0 mg intramuscularly daily for four days
Number of subjects: 32
Study 15998354 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH(1-24) 0.5 mg intramuscularly daily for four days
Number of subjects: 32
Study 15998354 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH(1-24) 0.1 mg intramuscularly daily for four days
Number of subjects: 32
Study 15998354 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% 1 ml intramuscularly daily for four days (Control)
Number of subjects: 32
Study 15998354 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH(1-24) 1.0 mg intramuscularly five times at an interval of four days
Number of subjects: 32
Study 12433013 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of nondrinkers
Number of subjects: 308
Study 12433013 — intervention group
Group type: COMPARATOR
Intervention: Images of drinkers
Number of subjects: 308
Study 9812915 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in adiposity before age 45
Number of subjects: 423
Study 9812915 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in adiposity after age 45
Number of subjects: 423
Study 9812915 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in adiposity
Number of subjects: 423
Study 9812915 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult levels of total cholesterol and low density lipoprotein cholesterol
Number of subjects: 423
Study 8043704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate treatment for 4 weeks
Number of subjects: 27
Study 8043704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate treatment
Number of subjects: 27
Study 3414571 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet‐plus‐behavior (DB) therapy
Number of subjects: 36
Study 3414571 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise‐plus‐diet‐plus‐behavior (EDB) therapy
Number of subjects: 36
Study 3414571 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 4877600 — intervention group
Group type: EXPERIMENTAL
Intervention: I.C.I. 50172 (20 mg)
Number of subjects: 0
Study 4877600 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (1 mg)
Number of subjects: 0
Study 4877600 — intervention group
Group type: EXPERIMENTAL
Intervention: I.C.I. 50172 (4 mg)
Number of subjects: 0
Study 4877600 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (4 mg)
Number of subjects: 0
Study 4877600 — intervention group
Group type: EXPERIMENTAL
Intervention: I.C.I. 50172
Number of subjects: 0
Study 4877600 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 29119418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at doses of 3, 6, and 9 J/diode (135, 270, and 405 J/thigh) applied bilaterally to the quadriceps muscle before time-to-exhaustion tests.
Number of subjects: 20
Study 29119418 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment applied bilaterally to the quadriceps muscle before time-to-exhaustion tests.
Number of subjects: 20
Study 28237959 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine 4-8 mg/day and fosinopril 20 mg/day
Number of subjects: 511
Study 28237959 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5-25 mg/day and fosinopril 20 mg/day
Number of subjects: 511
Study 25337748 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month gatifloxacin-containing regimen (400 mg per day)
Number of subjects: 1836
Study 25337748 — intervention group
Group type: COMPARATOR
Intervention: Standard 6-month regimen (including ethambutol during the 2-month intensive phase)
Number of subjects: 1836
Study 25337748 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month gatifloxacin-containing regimen
Number of subjects: 1836
Study 25337748 — intervention group
Group type: COMPARATOR
Intervention: Standard 6-month regimen
Number of subjects: 1836
Study 23335221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine plus docetaxel followed by doxorubicin
Number of subjects: 47
Study 20543271 — intervention group
Group type: EXPERIMENTAL
Intervention: eBaViR system during rehabilitation sessions
Number of subjects: 0
Study 20543271 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation sessions
Number of subjects: 0
Study 18787330 — intervention group
Group type: EXPERIMENTAL
Intervention: Galphimia glauca C12
Number of subjects: 15
Study 18787330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16834650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 367
Study 16834650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 367
Study 16834650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 12543744 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (PI) solution
Number of subjects: 105
Study 12543744 — intervention group
Group type: COMPARATOR
Intervention: 1% povidone-iodine (PI) solution
Number of subjects: 105
Study 10830649 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol candies
Number of subjects: 740
Study 10830649 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 740
Study 10830649 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 740
Study 8682520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic training protocol
Number of subjects: 0
Study 8682520 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training protocol
Number of subjects: 0